Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombosis | 3 | 2024 | 192 | 1.060 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 86 | 1.050 |
Why?
|
| Hemorrhage | 3 | 2024 | 273 | 0.980 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 43 | 0.910 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 46 | 0.860 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 67 | 0.850 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 100 | 0.840 |
Why?
|
| Rituximab | 2 | 2023 | 82 | 0.810 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 7 | 0.620 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 21 | 0.610 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 324 | 0.590 |
Why?
|
| Medical Marijuana | 2 | 2025 | 18 | 0.440 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 171 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 233 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 148 | 0.300 |
Why?
|
| Medical Oncology | 2 | 2025 | 57 | 0.280 |
Why?
|
| Aged | 11 | 2025 | 13873 | 0.250 |
Why?
|
| Humans | 19 | 2025 | 60912 | 0.230 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 75 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2023 | 7 | 0.220 |
Why?
|
| Hemostasis | 1 | 2024 | 20 | 0.220 |
Why?
|
| Vincristine | 1 | 2023 | 26 | 0.220 |
Why?
|
| Mutation | 2 | 2025 | 2485 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 585 | 0.220 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 76 | 0.220 |
Why?
|
| Prednisone | 1 | 2023 | 88 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.220 |
Why?
|
| Doxorubicin | 1 | 2023 | 99 | 0.210 |
Why?
|
| Female | 12 | 2025 | 31706 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 389 | 0.200 |
Why?
|
| Male | 12 | 2025 | 28424 | 0.200 |
Why?
|
| Anticoagulants | 2 | 2024 | 490 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 105 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 218 | 0.200 |
Why?
|
| Hematology | 1 | 2022 | 11 | 0.200 |
Why?
|
| Quarantine | 1 | 2021 | 10 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 302 | 0.180 |
Why?
|
| Curriculum | 1 | 2025 | 570 | 0.180 |
Why?
|
| Neoplasms | 2 | 2021 | 1269 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 409 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 335 | 0.170 |
Why?
|
| Chordoma | 1 | 2020 | 6 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2020 | 235 | 0.170 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
|
| Infection Control | 1 | 2021 | 98 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 703 | 0.160 |
Why?
|
| Hepatitis | 1 | 2019 | 56 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 170 | 0.150 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 114 | 0.150 |
Why?
|
| Middle Aged | 6 | 2025 | 16857 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 196 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 209 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2024 | 1958 | 0.140 |
Why?
|
| Risk Factors | 2 | 2024 | 5158 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2020 | 485 | 0.130 |
Why?
|
| Adult | 5 | 2025 | 16211 | 0.130 |
Why?
|
| Melanoma | 1 | 2020 | 336 | 0.130 |
Why?
|
| Urothelium | 1 | 2015 | 22 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 1134 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 62 | 0.110 |
Why?
|
| Prognosis | 3 | 2025 | 1629 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5347 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 132 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5289 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2023 | 2517 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6192 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 649 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 263 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 106 | 0.050 |
Why?
|
| Abatacept | 1 | 2023 | 63 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| Young Adult | 2 | 2025 | 4430 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 534 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 280 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 19 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 102 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 71 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 44 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 197 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 1 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 68 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2020 | 33 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 53 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 756 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 117 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 383 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 319 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 366 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 972 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 219 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 813 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 154 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 114 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 75 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 174 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 278 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 306 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 1116 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 152 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2642 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1280 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 636 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2401 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3661 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1321 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 931 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2073 | 0.020 |
Why?
|
| United States | 1 | 2023 | 7657 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6041 | 0.020 |
Why?
|